Nuvectis Reports 40% Response Rate for NXP200 in High-Grade Glioma, Including Three Complete Responses

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage company developing therapies for complement-related conditions and cancer, announced on October 26, 2026 expanded Phase 1b data for NXP200 in patients with BRAF V600-mutated gliomas, a type of brain tumor. The data, presented at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, showed a 40.0% objective response rate in high-grade glioma, including three complete responses.

Response Rates in High-Grade and Low-Grade Glioma

As of a May 4, 2026 cutoff, 27 efficacy-evaluable patients with recurrent or progressive glioma had received NXP200 as a single agent. Of those, 20 had high-grade glioma and seven had low-grade glioma. Investigators assessed response with the RANO 2.0 criteria used for brain tumors.

In the high-grade group, 8 of 20 patients responded, including three complete responses, one of which is preliminary. In the low-grade group, 3 of 7 responded, for a 42.9% response rate that includes one confirmed complete response. Across all 27 patients, 81.5% saw tumor reduction, and the disease control rate was 85.2%.

In addition, the company reported deep responses, defined as more than 80% tumor burden reduction, in 7 of 8 high-grade responders and 2 of 3 low-grade responders.

Durability, Prior BRAF Treatment and Safety

In high-grade glioma, the median duration of response was 6.97 months and median overall survival was 17.15 months. Meanwhile, 12-month survival was 95% in the high-grade group and 100% in the low-grade group. The low-grade group has not yet reached a median duration of response or median overall survival.

NXP200 is a second-generation, or paradox-breaker, BRAF inhibitor, designed to block the BRAF pathway without the paradoxical activation seen with first-generation drugs in this class. Among three patients who had previously received a BRAF inhibitor, two achieved a partial response and one had stable disease.

On safety, 14.3% of 28 safety-evaluable patients experienced a Grade 3 or higher treatment-related adverse event. No treatment-related adverse event led to discontinuation or death, and the company reported one serious adverse event, which it deemed unrelated to treatment.

Partnership and U.S. Development Plans

Haisco Pharmaceutical Group is running the Phase 1b study in China. In June 2026, Nuvectis in-licensed exclusive worldwide rights to NXP200 outside Greater China from Haisco. In addition, China’s Center for Drug Evaluation granted NXP200 Breakthrough Therapy Designation in September 2026 for BRAF V600-mutated recurrent or progressive high-grade glioma.

“We look forward to further updates from the ongoing Phase 1b program, including in additional tumor types, and we remain on track to submit a U.S. IND for NXP200 by the end of this year,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.

Beyond NXP200, the company’s pipeline includes ciprocopan (NXP100), a once-a-day complement Factor B inhibitor recently approved in China for previously untreated PNH patients, and NXP900, an oral SRC family kinase inhibitor.

Strategic Investment Summary

• ESMO Data: Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported a 40.0% objective response rate for NXP200 in high-grade glioma, including three complete responses, on October 26, 2026.
• Low-Grade Glioma: Three of seven low-grade glioma patients responded, including one confirmed complete response.
• Depth and Control: 81.5% of all 27 patients saw tumor reduction, and the disease control rate was 85.2%.
• Survival: High-grade patients showed 17.15 months median overall survival and 95% survival at 12 months.
• Prior BRAF Treatment: Two of three patients previously treated with a BRAF inhibitor achieved a partial response.
• Next Step: Nuvectis remains on track to submit a U.S. IND for NXP200 by the end of 2026.

Find out more about the latest corporate developments and financial reports at the Nuvectis investor portal.